![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![DPH Advises Vaccine Providers to Offer Pfizer COVID-19 Vaccine for Children 5 to 11 Years of Age - State of Delaware News DPH Advises Vaccine Providers to Offer Pfizer COVID-19 Vaccine for Children 5 to 11 Years of Age - State of Delaware News](https://news.delaware.gov/files/2021/11/Pfizer-COVID-Vaccine-Orange-Vials.jpg)
DPH Advises Vaccine Providers to Offer Pfizer COVID-19 Vaccine for Children 5 to 11 Years of Age - State of Delaware News
![Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet](https://www.thelancet.com/cms/attachment/caf9bf39-ae54-4e4f-a650-c7d3a3b705f9/gr1.jpg)
Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study - The Lancet
![Syringe size and supply issues continue to waste COVID-19 vaccine doses in United States | Science | AAAS Syringe size and supply issues continue to waste COVID-19 vaccine doses in United States | Science | AAAS](https://www.science.org/do/10.1126/science.abi6931/abs/Vaccine_waste_1280x720.jpg)
Syringe size and supply issues continue to waste COVID-19 vaccine doses in United States | Science | AAAS
![3rd COVID-19 Vaccine Dose for Certain Immunocompromised Individuals - Anne Arundel County Department of Health 3rd COVID-19 Vaccine Dose for Certain Immunocompromised Individuals - Anne Arundel County Department of Health](http://aahealth.org/wp-content/uploads/2021/08/iStock-1220396422.jpg)
3rd COVID-19 Vaccine Dose for Certain Immunocompromised Individuals - Anne Arundel County Department of Health
![Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7018e1_EffectivenessOlderAdults_IMAGE_28Apr21_1200x675.jpg)
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021 | MMWR
![US CDC recommends third dose of Pfizer and Moderna COVID-19 vaccines for immunocompromised people | aidsmap US CDC recommends third dose of Pfizer and Moderna COVID-19 vaccines for immunocompromised people | aidsmap](https://www.aidsmap.com/sites/default/files/styles/aidsmap_medium_crop/public/2021-08/2000x1300%20images-aidsmap-vaccine.png?itok=m9zjItoF)
US CDC recommends third dose of Pfizer and Moderna COVID-19 vaccines for immunocompromised people | aidsmap
![Vaccines | Free Full-Text | Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy Vaccines | Free Full-Text | Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy](https://www.mdpi.com/vaccines/vaccines-10-00539/article_deploy/html/images/vaccines-10-00539-g001.png)
Vaccines | Free Full-Text | Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy
![Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 | MMWR Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites, January–March 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7020e2_EffectivenessPfizerModernaHCP_IMAGE_14May21_1200x675.jpg)